Tag: GLP-1-agonists
Eli Lilly’s Obesity Drug Access: What We Know About FDA Approval Pathways
Regulatory pathways and corporate strategy shape early access to obesity drug candidates. Pharmaceutical acquisitions in the metabolic disease sector reflect…
Submit Your Paper to GMJ
No APC until January 2027.